Noram Lithium Corp. (TSXV:NRM)

CTI BioPharma Ratios and Metrics

Market cap in millions CAD. Fiscal year is February - January.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 1, 2025	Jan 31, 2025	Jan 31, 2024	Jan 31, 2023	Jan 31, 2022	Jan 31, 2021
Market Capitalization	8	8	17	79	62	60
Market Cap Growth	-24.66%	-53.56%	-78.09%	27.59%	4.06%	899.91%
Enterprise Value	8	7	11	64	60	58
Last Close Price	0.10	0.09	0.20	0.89	0.83	0.88
PB Ratio	1.57	1.39	2.18	5.84	11.50	12.69
P/TBV Ratio	1.57	1.39	2.18	5.84	11.50	12.69
Debt / Equity Ratio	0.03	0.03	0.01	0.01	0.03	0.01
Quick Ratio	0.65	1.46	7.70	19.51	3.76	4.89
Current Ratio	0.91	1.81	7.80	20.68	3.99	4.99
Return on Equity (ROE)	-50.39%	-45.87%	-52.67%	-49.72%	-105.44%	-131.48%
Return on Assets (ROA)	-28.61%	-27.46%	-34.76%	-32.34%	-59.69%	-74.97%
Return on Capital (ROIC)	-30.54%	-29.00%	-36.38%	-33.97%	-63.63%	-79.61%
Earnings Yield	-38.17%	-39.16%	-32.66%	-5.95%	-8.58%	-8.38%
FCF Yield	-26.06%	-36.96%	-49.54%	-7.57%	-3.85%	-2.20%
Buyback Yield / Dilution	-0.37%	-0.29%	-1.20%	-18.88%	-47.27%	-31.94%

Updated Dec 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.